Quintrio
Home

PHARMACEUTICAL PREPARATIONS

CervoMed Inc. Common Stock

CRVO

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Last trade $1.56
Day change -$0.11 (-6.59%)
Day range $1.55 – $1.75
Volume 240,350
Market cap $25M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$25.26M
Price / earnings
—
Price / book
1.46×
Price / sales
2,895.33×
EV / sales
2,200.88×
EV / EBITDA
-0.66×

Profitability

Earnings per share
-$1.89
Return on assets
-133.7%
Return on equity
-164.32%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.37×
Quick ratio
5.37×
Cash ratio
1.52×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$26.59M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CRVO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$8.73K$322.57K$1.76M$1.92M$2.16M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$8.73K$322.57K$1.76M$1.92M$2.16M
Selling, general and administrative$2.43M$2.36M$2.98M$2.51M$2.33M$3.27M$2.38M$2.32M
Research and development$3.68M$4.32M$5.14M$5.83M$6.04M$5.11M$4.84M$7.09M
Total operating expenses$6.1M$6.68M$8.11M$8.34M$8.37M$8.37M$7.22M$9.4M
Operating income-$6.1M-$6.68M-$8.11M-$8.33M-$8.04M-$6.62M-$5.3M-$7.24M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$5.9M-$6.57M-$7.96M-$8.09M-$7.73M-$6.26M-$4.89M-$6.71M
Income taxes$0$0$0$0$0$0$0$0
Net income-$5.9M-$6.57M-$7.96M-$8.09M-$7.73M-$6.26M-$4.89M-$6.71M
Net income attributable to common shareholders-$5.9M-$6.57M-$7.96M-$8.09M-$7.73M-$6.26M-$4.89M-$6.71M
EBITDA-$6.1M-$6.68M-$8.11M-$8.33M-$8.04M-$6.62M-$5.3M-$7.24M
Basic earnings per share-$0.39-$0.64-$0.86-$0.87-$0.84-$0.70-$0.56-$0.77
Diluted earnings per share-$0.39-$0.64-$0.86-$0.87-$0.84-$0.70-$0.56-$0.77

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Agenus (AGEN) Q3 Earnings Meet Estimates

Agenus (AGEN) reported Q3 2026 earnings of $0.02 per share, matching consensus estimates but missing revenue expectations by 10.03% at $31.49 million. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions, suggesting underperformance ahead. Despite a 122% year-to-date gain, the biotech company has only surpassed EPS estimates once in the last four quarters.

GlobeNewswire Inc.

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

CervoMed Inc. announced that its drug candidate neflamapimod has been selected for inclusion in the UK's EXPERTS-ALS platform, a government-funded clinical trial designed to rapidly test potential ALS treatments. The trial will initially evaluate neflamapimod in approximately 35 ALS patients over 18-24 weeks, with potential expansion to 80 patients. The selection is based on the drug's targeted mechanism of action and positive clinical data in dementia with Lewy bodies trials.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 19, 20221-for-50reverse split
Dec 14, 20181-for-15reverse split